EcoDrugPlus

Phosphodiesterase 5a

Ensembl ID : ENSCDRG00005003851
Gene Symbol: PDE5A
3 Cross references
208 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSCDRG00005020748
Gene Symbol: PDE7A
1 Cross references
240 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSCDRG00005018377
Gene Symbol: PDE7B
1 Cross references
174 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSCDRG00005011646
Gene Symbol: PDE9A
3 Cross references
193 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSCDRG00005004828
Gene Symbol: PIK3R1
3 Cross references
259 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSCDRG00005011973
Gene Symbol: PIK3R2
1 Cross references
253 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSCDRG00005018616
Gene Symbol: PIK3R3
3 Cross references
276 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSCDRG00005016417
Gene Symbol: PIK3R5
1 Cross references
255 Possible Orthologues:

Phospholipase A2 Group Iia

Ensembl ID : ENSCDRG00005008305
Gene Symbol: PLA2G2A
3 Cross references
168 Possible Orthologues:

Phospholipase A2 Group V

Ensembl ID : ENSCDRG00005008409
Gene Symbol: PLA2G5
1 Cross references
116 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSCDRG00005017578
Gene Symbol: PLA2G7
1 Cross references
206 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSCDRG00005013514
Gene Symbol: PLA2G10
1 Cross references
250 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).